House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
The FDA approved aducanumab earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness.
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.